Shaping the landscape of immune oncology in hepatocellular carcinoma
Mené sur 104 patients atteints d'un carcinome hépatocellulaire de stade avancé, cet essai de phase II non randomisé évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du pembrolizumab, après l'échec d'un traitement par sorafénib
Immune-based strategies have been tested for the treatment of hepatocellular carcinoma since the early 1990s and have yielded unsatisfactory results. However, with the advent of immune checkpoint inhibitors in 2013, which were announced as a major breakthrough in oncology,1 there was a renewed interest in immunotherapy as a potential therapeutic option for cancers that are difficult to treat, such as hepatocellular carcinoma.
The Lancet Oncology , commentaire, 2017